Renal Cell Carcinoma Perspective

 
 
  • Renal Cell Carcinoma: Factoring Risk   Drs Nicholas Vogelzang and Brian Rini discuss assessment tools that can inform the choice of treatment in metastatic renal cell carcinoma.
  • Plants That Can Poison, Harm, or Kill So many toxic plants, so many poisonings waiting to happen! Are you aware of the danger posed by these flowers and leaves?
  • Which Patients Will Progress to Kidney Failure After Surgery? Dr Badani describes a novel surgical procedure for treating kidney cancer and provides insight on the recent advances in predicting which patients will progress to kidney failure after surgery.
  • Biomarkers to Determine Who Gets Checkpoint Inhibitors   Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.
  • Renal Cell Carcinoma: The New Challenge   Two noted oncologists tackle a puzzling clinical question: What is the optimal sequence of therapies for patients with metastatic renal cell carcinoma?
  • Genitourinary Cancers Symposium (GUCS) 2017 Read clinically focused news coverage of key developments from GUCS 2017.
  • The Future of Cancer Drugs: RNA Therapies, Bacteria, and Viruses Several new classes of anti-cancer therapies are in development with the hope of becoming the next major advance in oncology.
  • New Therapies Take Aim at Brain Metastasis   Emerging research is uncovering new treatment options for brain metastasis, a common and dire consequence of many cancers. Dr Matthias Preusser highlights the latest findings from ESMO 2016.
  • Top News From ESMO 2016: Slideshow Practice-changing research in lung cancer; colorectal cancer; and breast, ovarian, and kidney cancer featured prominently at this year's congress.
  • A New Oncology Target: The Heart Delivering the most effective dose of chemotherapy without causing cardiotoxicity is a key goal of the emerging field of cardio-oncology. But are the current predictors of cardiotoxic risk adequate?
  • Is Immunotherapy Safe for Older Melanoma Patients?   How do adverse events from immunotherapy compare in younger vs older patients? Dr Weber comments on the safety of checkpoint inhibitors for our older patients.
  • Rethinking Cytoreductive Nephrectomy in Metastatic RCC Recent data suggest that cytoreductive nephrectomy may confer a significant survival advantage in metastatic renal cell carcinoma.
  • #ASCO16: Hot Topics on Twitter Social media activity using #ASCO16 at the ASCO annual meeting achieved record-breaking highs in many categories.
  • Cabozantinib a Possible New Standard in Second-line Metastatic RCC   Dr David Graham reviews the METEOR trial in metastatic renal cell carcinoma, one of the most important studies on genitourinary malignancies presented at ASCO 2016.
  • 'Think Different' About Clinical Cancer Research In the wake of Vice President Biden's talk at ASCO 2016, Dr David Graham suggests a new approach to collect data at the point of care to guide future clinical cancer treatments.
  • What to Watch for in Genitourinary Cancers This year's ASCO annual meeting will feature important developments in bladder cancer, renal cell carcinoma, and prostate cancer.
  • PD-1 Inhibitors Show Promise in Upper GI Cancers Early findings suggest that immunotherapies, such as PD-1 inhibitors, could play a large role in the management of upper GI cancers, as reported by Dr Brandon Smaglo from GISC 2016.
  • Genitourinary Cancers Symposium (GUCS) 2016 Read clinically focused news coverage of key developments from GUCS 2016.
  • Pembrolizumab Shows Durable Responses in TNBC   Single-agent PD-L1 antibodies in triple-negative breast cancer show exceptionally durable responses, raising hope for stronger responses with combination therapies, says Dr Hope Rugo from SABCS 2015.
  • Quiz: The Alcohol-Cancer Connection How much do you know about the link between alcohol and cancer and how this influences advice to patients?
Купить Левитра 60 мг

comprar viagra sin receta

farm-pump-ua.com/deka-durabolin.html